The increasingly international bribery investigation into British drugmaker GlaxoSmithKline has led to unusual cooperation between U.K. and Chinese anti-fraud officials.
David Green, director of the U.K.’s Serious Fraud Office (SFO), told Reuters in an interview last week that this is the first time he is aware of Chinese officials cooperating in an SFO case.
